Research
New data supports Hoya's DIMS lenses for myopic prevention among preschool-aged pediatrics
Presented at ARVO, updated findings among the younger pre-myopics confirmed a protective effect of the patented and embedded technology on refractive status.
Research
Hoya reports 8-year data on DIMS spectacle lenses for pediatric myopia
Long-term study evaluated myopia control effect and user experience of patients wearing HOYA’s MiYOSMART spectacle lenses.
Research
DIMS spectacle lenses may mitigate pediatric myopia
Second-ever 6-year clinical trial of myopia control shows no rebound effects after cessation of treatment lens wear.
Research
HOYA reports 6-month data on MiYOSMART iQ spectacle lenses for pediatric myopia
Interim results find advanced lens and D.I.M.S. triple enhanced design tech to be twice as effective in controlling axial elongation and disease progression.
Products
Hoya Vision launches spectacle lenses for pediatric myopia protection
The MiYOSMART photochromic and polarized spectacle lenses incorporate D.I.M.S. technology.
Research
Study: CV risk score identifies future eye disease risk
Pooled Cohort Equations (PCE) score may help identify high-risk patients when preventive measures may protect their vision.
Research
Study correlates visual impairment with sleep disruptions
Poor sleep quality associated with a significantly higher risk of visual impairment, diabetic retinopathy, and other ocular conditions.
Legal
Samsung Biopeis and Regeneron settle EYLEA biosimilar US patent dispute
Settlement and license agreement clears the way for a January 2027 commercial launch of OPUVIZ 2 mg (aflibercept-yszy) injection.
Research
Cannabis implicated in ocular inflammatory disease development
Cannabis use associated with higher risk of developing uveitis and other posterior segment diseases.
Pipeline
Novartis's ianalumab earns FDA Breakthrough Therapy designation for Sjögren’s disease
Fully human monoclonal antibody is delivered as a monthly subcutaneous injection; company plans to submit for global approval in early 2026.
Business
Topcon and RemoniHealth to advance AI-based chronic eye disease monitoring
New partnership will integrate remote at-home vision testing with Topcon’s connected care model to support ongoing Healthcare from the Eye initiative.
Research
Beta-zone PPA may be major glaucoma disease marker for Black patients
Beta-zone PPA was linked with RNFL thinning, suggesting it may be a feature of glaucomatous change.
Products
Euclid Vision launches new SiHy daily disposable lens for myopia
The Be Free Day soft lens for pediatric myopes features BHVI's proprietary dual action, multistep optical design technology.
Products
Rinsada expands irrigating eyelid retractor distribution to Canada
Already FDA-cleared in the U.S., the medical device is now registered by Health Canada and only available through online retailer Eye Drop Shop.
Research
Study: enVista Aspire IOL delivers expanded intermediate vision without sacrificing distance
Prospective study evaluates the enhanced monofocal IOL among patients undergoing standard phaco.
Pipeline
SeaBeLife and Unither to formulate and develop retinal degenerative disorder formulation
Collaboration focuses on accelerating development of SBL03, formulated for topical delivery to target retinal cell necrosis in GA and dry AMD.
Pipeline
Belite Bio reports phase 3 topline data on oral tinlarebant for Stargardt disease
DRAGON study is evaluating the once-daily tablet for reducing lesion growth among adolescent patients over a 24-month period.
Pipeline
Coave Therapeutics debuts lead SCS gene therapy for retinal vascular diseases
In-office, suprachoroidal delivery of CoTx-101 offers potential for durable and long-lasting vision gains in treating wet AMD and DME.
Products
Myopia Profile debuts AI virtual assistant for disease management
Ask Kate is trained to deliver real-time, evidence-based responses to help ECPs stay updated on the latest clinical and scientific research.
Research